Gaurav Shah, MD
Associate Professor of OphthalmologyWashington University Medical Center
Gaurav Shah, MD, is an Associate Professor of Ophthalmology at the Washington University Medical Center in Missouri. He is a national expert in the care of patients with diabetic retinopathy/diabetic macular edema, age-related macular degeneration, retinal detachments, and the economics of retinal health care. Dr. Shah is also involved in the development of new retinal surgical systems in vitreoretinal surgery. He has been involved in the pivotal trials and publications regarding Macugen, Lucentis, and PDT and is working on new combinations of PDT and Avastin. Dr. Shah has presented at many national and international meetings and has published over four book chapters and approximately 78 peer-reviewed articles. He is an elected member of the Retina Society, the Macula Society, and the American Academy of Ophthalmology. Dr. Shah is also a testing member of the American Board of Ophthalmology, teaches fellows at the university, and is the director of the retina fellowship program. (This is me - Update Profile)
| 1999 - present | Associate Professor of Ophthalmology Washington University Medical Center |
|---|
GLG Study Groups with Gaurav Shah, MD(?)
| Study Group Name | Members |
|---|---|
| Ophthalmologists (US) | 1036 |
| Physicians who Implant Intraocular Lenses | 197 |
| Ophthalmologists who Treat Macular Degeneration (US) | 139 |
| Vitreoretinal Surgeons (US) | 153 |
GLG NewsSM Analyses by Gaurav Shah, MD(?)
1. A molecule that allows on to stop neovascular armd to form from dry armd 2. A product with a potentially large market share compared to the current agents available 3. A compound that could have a sustained drug delivery module
PDT remains a viable option for patients with new blood vessels from high myopia. Despite the era of antivegf therapy PDT may be safer in these patients than repeated injection. This article yet again defies another area for the use of PDT. PDT will be continued to be complemented to the currently available...
It is not surprising that laser therapy is not effective for patients with macular degeneration. Initially there was a significant interest in this therapy, but as this well designed trial has shown us that thermal treatment is not the answer for dry ARMD. AREDS I and AREDS II are now the most important...
GLG InstituteSM Seminars with Gaurav Shah, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Gaurav Shah, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms